René Dörfelt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
René Dörfelt has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Katrin Hartmann
LMU Small Animal Clinic, Center for Clinical Veterinary Medicine, Faculty of Veterinary Medicine Ludwig‐Maximilians‐Universität München Munich Germany
10 shared publications- Florian Sänger
Ludwig-Maximilians-Universität Small Animal Clinic, Centre for Clinical Veterinary Medicine, Faculty of Veterinary Medicine, Ludwig-Maximilians-Universität München, Munich, Germany
7 shared publications - Katrin Hartmann
LMU Small Animal Clinic, Centre for Clinical Veterinary Medicine, LMU Munich, Germany
5 shared publications - Roswitha Dorsch
LMU Small Animal Clinic, Centre for Clinical Veterinary Medicine, LMU Munich, Germany
3 shared publications - Dschaniena Kiwitz
Affiliation Veterinary Clinic for Small Animals, Tierklinik Hofheim, Tierärzte IVC Evidensia GmbH, Hofheim am Taunus, Hessen, Germany
2 shared publications - Gerhard Wess
LMU Small Animal Clinic, Ludwig-Maximilians-University, Germany
2 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- p. 1-8
Hemoadsorption with the Cytosorb adsorber can effectively reduce cell-free hemoglobin from porcine blood in vitro
Objective: The aim of this study was to investigate the maximum capacity of the Cytosorb adsorber for clearance of cell-free hemoglobin (cfHb) in a porcine cfHb solution in vitro. Methods: Anticoagulated porcine blood was centrifuged to separate plasma from RBCs. Red blood cell concentrate was stored in the freezer, thawed, and mixed with distilled water to achieve complete hemolysis. The cfHb solution was divided into 12 aliquots of 1,000 mL each. Six test runs were performed in a circular setup with the Cytosorb adsorber. Samples were collected before and after adsorber. After 20 L of processed cfHb solution, the storage bottle was exchanged, and a new storage bottle with 1,000 mL of the cfHb solution with the initial cfHb concentration was processed for another 10 L. Results: The initial median cfHb concentration of the porcine cfHb solution of 4.13 mmol/L (4.03 to 4.22 mmol/L) decreased to 2.70 mmol/L (2.54 to 2.79 mmol/L) after processing 20 L of cfHb solution. This corresponds to a median cfHb reduction of 22.1 g (21.9 to 27.1 g), which was primarily achieved during the first 10.0 L of processed cfHb solution. In the second storage bottle, no further relevant cfHb concentration decrease was achieved. Conclusions: Hemoadsorption using the Cytosorb adsorber effectively reduced cfHb concentration from a porcine cfHb solution in vitro. The maximum adsorption capacity of the Cytosorb adsorber for this experimental setup was about 22.1 g. Clinical Relevance: The Cytosorb adsorber might be a promising tool for removal of cfHb from the circulation in vivo.
- 24 September 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- p. 1-8
Open AccessHemoadsorption with the Cytosorb adsorber can effectively reduce cell-free hemoglobin from porcine blood in vitro
Objective: The aim of this study was to investigate the maximum capacity of the Cytosorb adsorber for clearance of cell-free hemoglobin (cfHb) in a porcine cfHb solution in vitro. Methods: Anticoagulated porcine blood was centrifuged to separate plasma from RBCs. Red blood cell concentrate was stored in the freezer, thawed, and mixed with distilled water to achieve complete hemolysis. The cfHb solution was divided into 12 aliquots of 1,000 mL each. Six test runs were performed in a circular setup with the Cytosorb adsorber. Samples were collected before and after adsorber. After 20 L of processed cfHb solution, the storage bottle was exchanged, and a new storage bottle with 1,000 mL of the cfHb solution with the initial cfHb concentration was processed for another 10 L. Results: The initial median cfHb concentration of the porcine cfHb solution of 4.13 mmol/L (4.03 to 4.22 mmol/L) decreased to 2.70 mmol/L (2.54 to 2.79 mmol/L) after processing 20 L of cfHb solution. This corresponds to a median cfHb reduction of 22.1 g (21.9 to 27.1 g), which was primarily achieved during the first 10.0 L of processed cfHb solution. In the second storage bottle, no further relevant cfHb concentration decrease was achieved. Conclusions: Hemoadsorption using the Cytosorb adsorber effectively reduced cfHb concentration from a porcine cfHb solution in vitro. The maximum adsorption capacity of the Cytosorb adsorber for this experimental setup was about 22.1 g. Clinical Relevance: The Cytosorb adsorber might be a promising tool for removal of cfHb from the circulation in vivo.
- Open Access
- 1 June 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (6)
Hematological changes after intermittent hemodialysis in dogs with acute kidney injury are mild and transient
Objective: To evaluate hematological changes in dogs with acute kidney injury caused by different underlying disease processes treated with intermittent hemodialysis (IHD) over 12 to 24 hours after the session. Methods: Client-owned dogs with acute kidney injury treated with IHD from February 2021 through July 2025 were prospectively enrolled in this observational study. Blood was collected from each dog before IHD (T0), after IHD (T1), and 12 to 24 hours after IHD (T2). Hematocrit, RBC count, hemoglobin concentration, reticulocyte count, platelet count, and WBC count were evaluated at all time points. Results: In total, 30 dogs with 82 IHD sessions were included in the study. Median RBC count (X 10 12 /L) and median hemoglobin concentration (mmol/L) decreased from 4.00 (2.82 to 7.22) and 9.25 (6.60 to 17.20) at T0 to 3.74 (2.39 to 7.04) and 9.00 (5.50 to 16.80) at T1, respectively. Median WBC count (X 10 9 /L) of 19.34 (6.49 to 55.47) at T0 decreased to 17.6 (4.57 to 73.22) at T1 and increased to 20.11 (7.48 to 55.47) at T2. Median platelet count (X 10 9 /L) of 99 (5 to 767) at T0 decreased to 69 (1 to 633) at T1 and increased to 84 (4 to 604) at T2. Conclusions: Hematological changes during IHD were mild and transient. Only the platelet count decreased moderately. Clinical Relevance: Most of the hematological changes did not appear clinically relevant and resolved within 24 hours. However, the moderate decrease in platelet count could potentially predispose dogs undergoing IHD to an increased risk of bleeding.
- 1 June 2026
- Published by American Veterinary Medical Association (AVMA) in American Journal of Veterinary Research
- Vol. 87 (6)
Open AccessHematological changes after intermittent hemodialysis in dogs with acute kidney injury are mild and transient
Objective: To evaluate hematological changes in dogs with acute kidney injury caused by different underlying disease processes treated with intermittent hemodialysis (IHD) over 12 to 24 hours after the session. Methods: Client-owned dogs with acute kidney injury treated with IHD from February 2021 through July 2025 were prospectively enrolled in this observational study. Blood was collected from each dog before IHD (T0), after IHD (T1), and 12 to 24 hours after IHD (T2). Hematocrit, RBC count, hemoglobin concentration, reticulocyte count, platelet count, and WBC count were evaluated at all time points. Results: In total, 30 dogs with 82 IHD sessions were included in the study. Median RBC count (X 10 12 /L) and median hemoglobin concentration (mmol/L) decreased from 4.00 (2.82 to 7.22) and 9.25 (6.60 to 17.20) at T0 to 3.74 (2.39 to 7.04) and 9.00 (5.50 to 16.80) at T1, respectively. Median WBC count (X 10 9 /L) of 19.34 (6.49 to 55.47) at T0 decreased to 17.6 (4.57 to 73.22) at T1 and increased to 20.11 (7.48 to 55.47) at T2. Median platelet count (X 10 9 /L) of 99 (5 to 767) at T0 decreased to 69 (1 to 633) at T1 and increased to 84 (4 to 604) at T2. Conclusions: Hematological changes during IHD were mild and transient. Only the platelet count decreased moderately. Clinical Relevance: Most of the hematological changes did not appear clinically relevant and resolved within 24 hours. However, the moderate decrease in platelet count could potentially predispose dogs undergoing IHD to an increased risk of bleeding.
- Open Access
- 1 May 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (3) , e70130
Evaluation of Hemoadsorption Capacity of the CytoSorb Adsorber for Toxic Doses of Diclofenac and Meloxicam in Porcine Plasma
The objective of this in vitro experimental was to determine the utility of hemoadsorption (HA) using the CytoSorb adsorber to remove meloxicam and diclofenac from porcine plasma. For this purpose 12 1‐L aliquots of porcine plasma, 6 units were spiked with 293 μg/mL (262–320 μg/mL) diclofenac and 6 with 42.8 μg/mL (41.4–44.7 μg/mL) meloxicam, respectively. Each unit was processed in a circular setup with the CytoSorb adsorber using the PuriFi HA platform until a recirculated volume of 20 L was reached. Pre‐ and post‐adsorber samples were obtained at seven time points. Percentage reduction, clearance, and change from baseline were calculated. Drug concentrations were compared using Friedmann test with post hoc Dunn's multiple comparison test and Wilcoxon matched pairs rank sum test. p < 0.05 were considered significant. Diclofenac was reduced by a median of 242 mg (204–262 mg; 82.1%; 77.0%–83.6%). Total clearance was 40.5 mL/min (33.2–46.2 mL/min). Clearance at a plasma flow of 100 mL/min decreased from 39.9 mL/min (25.3–46.6 mL/min) at 0.2 L to 6.4 mL/min (−3.8 to 14.8 mL/min) at 20 L. Median reduction of meloxicam was 40.4 mg (38.6–42.2 mg; 94.4%; 93.2%–94.6%); total clearance was 94.38 mL/min (93.2–94.6 mL/min). Clearance at a plasma flow of 100 mL/min decreased from 65.3 mL/min (56.7–71.7 mL/min) at 0.2 L to 3.6 mL/min (−13.0 to 4.2 mL/min) at 20 L. HA using the CytoSorb adsorber successfully removed meloxicam and diclofenac from porcine plasma.
- 1 May 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (3) , e70130
Open AccessEvaluation of Hemoadsorption Capacity of the CytoSorb Adsorber for Toxic Doses of Diclofenac and Meloxicam in Porcine Plasma
The objective of this in vitro experimental was to determine the utility of hemoadsorption (HA) using the CytoSorb adsorber to remove meloxicam and diclofenac from porcine plasma. For this purpose 12 1‐L aliquots of porcine plasma, 6 units were spiked with 293 μg/mL (262–320 μg/mL) diclofenac and 6 with 42.8 μg/mL (41.4–44.7 μg/mL) meloxicam, respectively. Each unit was processed in a circular setup with the CytoSorb adsorber using the PuriFi HA platform until a recirculated volume of 20 L was reached. Pre‐ and post‐adsorber samples were obtained at seven time points. Percentage reduction, clearance, and change from baseline were calculated. Drug concentrations were compared using Friedmann test with post hoc Dunn's multiple comparison test and Wilcoxon matched pairs rank sum test. p < 0.05 were considered significant. Diclofenac was reduced by a median of 242 mg (204–262 mg; 82.1%; 77.0%–83.6%). Total clearance was 40.5 mL/min (33.2–46.2 mL/min). Clearance at a plasma flow of 100 mL/min decreased from 39.9 mL/min (25.3–46.6 mL/min) at 0.2 L to 6.4 mL/min (−3.8 to 14.8 mL/min) at 20 L. Median reduction of meloxicam was 40.4 mg (38.6–42.2 mg; 94.4%; 93.2%–94.6%); total clearance was 94.38 mL/min (93.2–94.6 mL/min). Clearance at a plasma flow of 100 mL/min decreased from 65.3 mL/min (56.7–71.7 mL/min) at 0.2 L to 3.6 mL/min (−13.0 to 4.2 mL/min) at 20 L. HA using the CytoSorb adsorber successfully removed meloxicam and diclofenac from porcine plasma.
- Open Access
- 3 October 2025
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 27 (11)
Nucleated red blood cells in critically ill cats
Objectives: This study investigated the presence of nucleated red blood cells (NRBCs) in the circulation as a prognostic factor in critically ill cats. Methods: Critically ill cats were prospectively included over 11 months if they fulfilled at least 3/4 systemic inflammatory response syndrome (SIRS) criteria or if their general condition was severely reduced. All cats underwent a physical examination and blood collection for haematological and clinical chemical parameters, including NRBCs at admission and during hospitalisation. Outcome was defined as survival to 28 days after discharge from hospital. For manual microscopic NRBC count, 300 nucleated cells were examined and recorded as relative NRBC count (rNRBC). Absolute NRBC (aNRBC) numbers were calculated from those values: aNRBC = rNRBC × (white blood cell [WBC]/100). Results: NRBCs, and most commonly metarubricytes, were detected in 25/94 critically ill cats. Primary underlying diseases were infectious (n = 10), neoplastic (n = 33), metabolic (n = 29), cardiovascular (n = 10), neurological (n = 5) and miscellaneous (n = 7). A positive correlation of absolute NRBCs with corrected WBCs ( r = 0.448) was observed. After 28 days, 18 cats were still alive and 76 cats did not survive. Mortality did not differ between NRBC-positive and NRBC-negative cats ( P = 0.641). Absolute NRBC count was 0.382 × 10 9 /l (range 0.032–28.990) and did not differ between survivors and non-survivors. Anaemia was not associated with NRBCs. All but one of the six NRBC-positive cats on day 2 did not survive. Conclusions and relevance: NRBCs can be observed in the blood of critically ill cats; however, their occurrence did not have a prognostic value.
- 3 October 2025
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 27 (11)
Open AccessNucleated red blood cells in critically ill cats
Objectives: This study investigated the presence of nucleated red blood cells (NRBCs) in the circulation as a prognostic factor in critically ill cats. Methods: Critically ill cats were prospectively included over 11 months if they fulfilled at least 3/4 systemic inflammatory response syndrome (SIRS) criteria or if their general condition was severely reduced. All cats underwent a physical examination and blood collection for haematological and clinical chemical parameters, including NRBCs at admission and during hospitalisation. Outcome was defined as survival to 28 days after discharge from hospital. For manual microscopic NRBC count, 300 nucleated cells were examined and recorded as relative NRBC count (rNRBC). Absolute NRBC (aNRBC) numbers were calculated from those values: aNRBC = rNRBC × (white blood cell [WBC]/100). Results: NRBCs, and most commonly metarubricytes, were detected in 25/94 critically ill cats. Primary underlying diseases were infectious (n = 10), neoplastic (n = 33), metabolic (n = 29), cardiovascular (n = 10), neurological (n = 5) and miscellaneous (n = 7). A positive correlation of absolute NRBCs with corrected WBCs ( r = 0.448) was observed. After 28 days, 18 cats were still alive and 76 cats did not survive. Mortality did not differ between NRBC-positive and NRBC-negative cats ( P = 0.641). Absolute NRBC count was 0.382 × 10 9 /l (range 0.032–28.990) and did not differ between survivors and non-survivors. Anaemia was not associated with NRBCs. All but one of the six NRBC-positive cats on day 2 did not survive. Conclusions and relevance: NRBCs can be observed in the blood of critically ill cats; however, their occurrence did not have a prognostic value.
- Open Access
- 28 September 2025
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 27 (9)
Evaluation of different doses of medetomidine for the induction of emesis in cats
Objectives: This study aimed to investigate the emetic effect of medetomidine, determine the best dose for clinical practice and investigate any adverse effects at different doses. Methods: In this prospective, observational study, 10, 20, 30 and 40 µg/kg of medetomidine was administered intramuscularly (IM) to cats after ingestion of foreign substances, to induce emesis. The success rate, frequency, time after injection, sedation score and adverse effects were recorded. If induction of emesis was not successful after 10 or 20 µg/kg medetomidine, a second bolus of medetomidine (20 µg/kg IM) was administered 10 mins later. Results: A total of 58 cats were included after foreign material ingestion. Emesis was achieved with all doses of medetomidine (39/58), whereby the highest success rate was reached with 20 µg/kg (13/17). The success rate after the first injection was not statistically different between the different medetomidine doses ( P = 0.457). The median time to emesis after the first injection of medetomidine for all cats was 5 mins (range 3–14). The sedation score was lower after 10 µg/kg medetomidine compared with 40 µg/kg ( P = 0.013). The most common adverse effect was sedation. Medetomidine was antagonised with atipamezole in 47/58 cats. Conclusions and relevance: Medetomidine is an effective drug for inducing emesis in cats and is a reasonable alternative to other alpha 2 -agonists. The most successful dose with the least adverse effects was 20 µg/kg IM.
- 28 September 2025
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 27 (9)
Open AccessEvaluation of different doses of medetomidine for the induction of emesis in cats
Objectives: This study aimed to investigate the emetic effect of medetomidine, determine the best dose for clinical practice and investigate any adverse effects at different doses. Methods: In this prospective, observational study, 10, 20, 30 and 40 µg/kg of medetomidine was administered intramuscularly (IM) to cats after ingestion of foreign substances, to induce emesis. The success rate, frequency, time after injection, sedation score and adverse effects were recorded. If induction of emesis was not successful after 10 or 20 µg/kg medetomidine, a second bolus of medetomidine (20 µg/kg IM) was administered 10 mins later. Results: A total of 58 cats were included after foreign material ingestion. Emesis was achieved with all doses of medetomidine (39/58), whereby the highest success rate was reached with 20 µg/kg (13/17). The success rate after the first injection was not statistically different between the different medetomidine doses ( P = 0.457). The median time to emesis after the first injection of medetomidine for all cats was 5 mins (range 3–14). The sedation score was lower after 10 µg/kg medetomidine compared with 40 µg/kg ( P = 0.013). The most common adverse effect was sedation. Medetomidine was antagonised with atipamezole in 47/58 cats. Conclusions and relevance: Medetomidine is an effective drug for inducing emesis in cats and is a reasonable alternative to other alpha 2 -agonists. The most successful dose with the least adverse effects was 20 µg/kg IM.
- Open Access
- 28 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0328306
Pilot study: In vitro reduction of hemoglobin from canine blood with hemoperfusion using the Cytosorb® adsorber
Cell-free hemoglobin (cfHb) can be toxic and lead to kidney injury. This study assessed the in vitro reduction of cfHb from canine hemolyzed blood using hemoperfusion with a Cytosorb® cytokine adsorber. Canine whole blood was processed in linear and circular setups, with three runs each, at 100 mL/min. Hemolysis and osmolarity adjustments were performed with distilled water and hypertonic saline. Anticoagulation was optimized with heparin (10,000 IU/L). A median of 3.38 L of hemoglobin solution was processed in the linear setup. Samples were collected after the adsorber and from the waste bag. In the circular setup, a median of 2.09 L was processed, with samples taken before and after the adsorber. CfHb concentration was measured using the XT-2000iV® hematology analyzer (Sysmex). A control setup without an adsorber was run for 24 hours to assess cfHb stability. In the linear setup, cfHb concentration decreased by a median of 17.8% (14.7–26.8%), from 1.7 mmol/L to a minimum of 0.9 mmol/L, with 12.1 g (11.9–23.5 g) of cfHb removed. The median cfHb concentration after the adsorber displayed a logarithmic increase from 0.9 mmol/L (0.8–1.2 mmol/L) to 1.6 mmol/L (1.4–2.1 mmol/L). After processing 2.4 L, no further reduction occurred. In the circular setup, cfHb was reduced by a median of 41.3% (46.1–45.0%), representing 17.4 g (14.6–19.0 g) removed after 13.0 L (13.0–14.0 L). The reduction plateau was reached after 13 L. The hemoglobin reduction ratio in the circular setup at 3 L processed cfHb-solution was 25.0% (23.1–33.3%) and was not different from the linear setup (p = 0.400). The cfHb clearance decreased in both setups over time. CfHb concentration in the control setup was stable for 24 hours. Hemoperfusion with the Cytosorb® adsorber reduced cfHb in vitro from a canine blood solution.
- 28 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0328306
Open AccessPilot study: In vitro reduction of hemoglobin from canine blood with hemoperfusion using the Cytosorb® adsorber
Cell-free hemoglobin (cfHb) can be toxic and lead to kidney injury. This study assessed the in vitro reduction of cfHb from canine hemolyzed blood using hemoperfusion with a Cytosorb® cytokine adsorber. Canine whole blood was processed in linear and circular setups, with three runs each, at 100 mL/min. Hemolysis and osmolarity adjustments were performed with distilled water and hypertonic saline. Anticoagulation was optimized with heparin (10,000 IU/L). A median of 3.38 L of hemoglobin solution was processed in the linear setup. Samples were collected after the adsorber and from the waste bag. In the circular setup, a median of 2.09 L was processed, with samples taken before and after the adsorber. CfHb concentration was measured using the XT-2000iV® hematology analyzer (Sysmex). A control setup without an adsorber was run for 24 hours to assess cfHb stability. In the linear setup, cfHb concentration decreased by a median of 17.8% (14.7–26.8%), from 1.7 mmol/L to a minimum of 0.9 mmol/L, with 12.1 g (11.9–23.5 g) of cfHb removed. The median cfHb concentration after the adsorber displayed a logarithmic increase from 0.9 mmol/L (0.8–1.2 mmol/L) to 1.6 mmol/L (1.4–2.1 mmol/L). After processing 2.4 L, no further reduction occurred. In the circular setup, cfHb was reduced by a median of 41.3% (46.1–45.0%), representing 17.4 g (14.6–19.0 g) removed after 13.0 L (13.0–14.0 L). The reduction plateau was reached after 13 L. The hemoglobin reduction ratio in the circular setup at 3 L processed cfHb-solution was 25.0% (23.1–33.3%) and was not different from the linear setup (p = 0.400). The cfHb clearance decreased in both setups over time. CfHb concentration in the control setup was stable for 24 hours. Hemoperfusion with the Cytosorb® adsorber reduced cfHb in vitro from a canine blood solution.
- Open Access
- 19 June 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1585168
Nucleated red blood cells as a prognostic indicator in dogs with anemia
Background: In human medicine, nucleated red blood cells (NRBCs) in the peripheral blood have been associated with a poor prognosis and increased mortality in critically ill patients. In critically ill dogs, mortality was also significantly associated with high peripheral NRBC count.Objective: This study aimed to determine the presence of NRBCs in the peripheral blood of dogs with regenerative and non-regenerative anemia and to evaluate the prognostic relevance of NRBCs in anemic dogs. Furthermore, the correlation between NRBCs and other blood parameters was examined.Materials and methods: Medical records of 254 anemic dogs hospitalized from November 2013 to June 2020 were retrospectively reviewed. Inclusion criteria were a hematocrit of p-values p < 0.001]. NRBCs were more often present in dogs with regenerative anemia (141/167) than in dogs with non-regenerative anemia (35/62; p < 0.001). The NRBC concentration was not different between surviving and non-surviving dogs (p = 0.080). An increase or decrease of NRBCs during hospitalization was also not associated with outcome.Conclusion: NRBCs commonly appear in the peripheral blood of dogs with regenerative anemia. Their presence and quantity are not associated with survival.
- 19 June 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1585168
Open AccessNucleated red blood cells as a prognostic indicator in dogs with anemia
Background: In human medicine, nucleated red blood cells (NRBCs) in the peripheral blood have been associated with a poor prognosis and increased mortality in critically ill patients. In critically ill dogs, mortality was also significantly associated with high peripheral NRBC count.Objective: This study aimed to determine the presence of NRBCs in the peripheral blood of dogs with regenerative and non-regenerative anemia and to evaluate the prognostic relevance of NRBCs in anemic dogs. Furthermore, the correlation between NRBCs and other blood parameters was examined.Materials and methods: Medical records of 254 anemic dogs hospitalized from November 2013 to June 2020 were retrospectively reviewed. Inclusion criteria were a hematocrit of p-values p < 0.001]. NRBCs were more often present in dogs with regenerative anemia (141/167) than in dogs with non-regenerative anemia (35/62; p < 0.001). The NRBC concentration was not different between surviving and non-surviving dogs (p = 0.080). An increase or decrease of NRBCs during hospitalization was also not associated with outcome.Conclusion: NRBCs commonly appear in the peripheral blood of dogs with regenerative anemia. Their presence and quantity are not associated with survival.
- Open Access
- 7 January 2025
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 27 (1)
Effect of acetate- and lactate-containing intravenous fluid on acid-base status, electrolytes and plasma lactate concentration in dehydrated cats
Objectives: Acetate (ACE) and lactate (LAC)-containing balanced resuscitation fluids are commonly used for fluid therapy in cats. These fluids can influence acid-base and electrolyte status. This prospective randomised study compared two balanced crystalloid solutions regarding their effect on acid-base status, electrolytes and LAC concentrations in dehydrated cats after intravenous fluid therapy. Methods: A total of 100 client-owned cats presenting to the emergency service with dehydration ⩾5% due to diarrhoea, vomiting or anorexia were included in this study. They were randomised to receive either ACE- (Sterofundin ISO; B Braun Vet Care) or LAC-containing (Ringer-Laktat nach Hartmann; B. Braun Vet Care) fluids for rehydration. Exclusion criteria were age <6 months, severe electrolyte abnormalities, severely increased creatinine or bolus therapy, and decompensated heart disease and liver diseases. Vital parameters were assessed and venous blood gas analysis was performed before and after fluid therapy. Data were analysed using the Mann–Whitney U-test and the Wilcoxon matched-pairs signed-rank test. The significance level was set at P ⩽0.05. Results: Post-rehydration pH normalised, and bicarbonate and base excess increased in both groups. Anion gap and LAC and potassium concentrations decreased in both groups. No difference in electrolyte, acid-base status and LAC was observed between cats receiving ACE and cats receiving LAC. Conclusions and relevance: Both fluids have similar effects on dehydrated cats’ acid-base status and electrolyte and LAC concentrations. No significant differences in values were found between ACE- and LAC-containing resuscitation fluids. Blood LAC concentration decreased in both groups.
- 7 January 2025
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 27 (1)
Open AccessEffect of acetate- and lactate-containing intravenous fluid on acid-base status, electrolytes and plasma lactate concentration in dehydrated cats
Objectives: Acetate (ACE) and lactate (LAC)-containing balanced resuscitation fluids are commonly used for fluid therapy in cats. These fluids can influence acid-base and electrolyte status. This prospective randomised study compared two balanced crystalloid solutions regarding their effect on acid-base status, electrolytes and LAC concentrations in dehydrated cats after intravenous fluid therapy. Methods: A total of 100 client-owned cats presenting to the emergency service with dehydration ⩾5% due to diarrhoea, vomiting or anorexia were included in this study. They were randomised to receive either ACE- (Sterofundin ISO; B Braun Vet Care) or LAC-containing (Ringer-Laktat nach Hartmann; B. Braun Vet Care) fluids for rehydration. Exclusion criteria were age <6 months, severe electrolyte abnormalities, severely increased creatinine or bolus therapy, and decompensated heart disease and liver diseases. Vital parameters were assessed and venous blood gas analysis was performed before and after fluid therapy. Data were analysed using the Mann–Whitney U-test and the Wilcoxon matched-pairs signed-rank test. The significance level was set at P ⩽0.05. Results: Post-rehydration pH normalised, and bicarbonate and base excess increased in both groups. Anion gap and LAC and potassium concentrations decreased in both groups. No difference in electrolyte, acid-base status and LAC was observed between cats receiving ACE and cats receiving LAC. Conclusions and relevance: Both fluids have similar effects on dehydrated cats’ acid-base status and electrolyte and LAC concentrations. No significant differences in values were found between ACE- and LAC-containing resuscitation fluids. Blood LAC concentration decreased in both groups.
- Open Access
- 29 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0298828
Clinical effects and adverse effects of intravenous lipid emulsion treatment in dogs and cats with suspected poisoning
This retrospective study aimed to evaluate the effects on the clinical signs of poisoning and adverse effects of intravenous lipid emulsion treatment in 82 animals (dogs and cats) with suspected poisonings over 18 months. Physical examination parameters and state of consciousness were documented every hour after the intravenous administration of a bolus of 2 ml/kg and 0.25 ml/kg/min over 60 minutes of a 20% intravenous lipid emulsion. The modified Glasgow coma scale and laboratory findings (blood gas analysis, triglyceride, lactate) were evaluated initially and three hours after discontinuing intravenous lipid emulsion administration. A statistical evaluation of the occurrence of adverse effects and the development of laboratory values was performed. A decrease in respiratory rate in the second control (8–12 hours) after ILE was observed. Three hours after completing of the intravenous lipid emulsion, triglyceride concentration increased about 10 times (p <0.001). Venous carbon dioxide partial pressure, bicarbonate, base excess, as well as the electrolytes sodium, potassium and ionized calcium decreased significantly (p <0.001). Patients who experienced a worsening of the modified Glasgow coma scale had a higher increase in triglyceride concentrations (p = 0.041) and plasma lactate (p = 0.034) and a larger decrease in bicarbonate concentrations (p = 0.053) compared to others. About 54% (n = 44) of the patients showed adverse effects which could be attributed to the administration of intravenous lipid emulsion and may be associated with a higher triglyceride increase. All of them were completely reversible within 33 hours. Adverse effects associated with intravenous lipid emulsion therapy were observed in half of the patients and were associated with a higher increase in triglycerides.
- 29 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0298828
Open AccessClinical effects and adverse effects of intravenous lipid emulsion treatment in dogs and cats with suspected poisoning
This retrospective study aimed to evaluate the effects on the clinical signs of poisoning and adverse effects of intravenous lipid emulsion treatment in 82 animals (dogs and cats) with suspected poisonings over 18 months. Physical examination parameters and state of consciousness were documented every hour after the intravenous administration of a bolus of 2 ml/kg and 0.25 ml/kg/min over 60 minutes of a 20% intravenous lipid emulsion. The modified Glasgow coma scale and laboratory findings (blood gas analysis, triglyceride, lactate) were evaluated initially and three hours after discontinuing intravenous lipid emulsion administration. A statistical evaluation of the occurrence of adverse effects and the development of laboratory values was performed. A decrease in respiratory rate in the second control (8–12 hours) after ILE was observed. Three hours after completing of the intravenous lipid emulsion, triglyceride concentration increased about 10 times (p <0.001). Venous carbon dioxide partial pressure, bicarbonate, base excess, as well as the electrolytes sodium, potassium and ionized calcium decreased significantly (p <0.001). Patients who experienced a worsening of the modified Glasgow coma scale had a higher increase in triglyceride concentrations (p = 0.041) and plasma lactate (p = 0.034) and a larger decrease in bicarbonate concentrations (p = 0.053) compared to others. About 54% (n = 44) of the patients showed adverse effects which could be attributed to the administration of intravenous lipid emulsion and may be associated with a higher triglyceride increase. All of them were completely reversible within 33 hours. Adverse effects associated with intravenous lipid emulsion therapy were observed in half of the patients and were associated with a higher increase in triglycerides.
- Open Access
- 1 March 2024
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 262 (3) , 1-7
Advantages of laparoscopic-assisted ovariohysterectomy versus open ovariohysterectomy for dogs with pyometra not detected in randomized clinical trial
OBJECTIVE: To compare results for surgery time, perioperative pain, need for rescue analgesia, variables, serum C-reactive protein concentration, and postoperative complications for dogs with pyometra treated with laparoscopic-assisted ovariohysterectomy (LaOVH) versus open-surgery (OS) ovariohysterectomy. ANIMALS: 12 client-owned dogs with pyometra between June 1, 2016, and December 31, 2019. METHODS: Dogs enrolled in this prospective single-center randomized clinical trial had pyometra confirmed by history, physical examination, ultrasonography, and blood work and were randomly assigned to treatment group LaOVH or OS. Differences in results for variables of interest were compared between groups using the Mann-Whitney U test, except the number of dogs requiring rescue analgesia was analyzed using the Fisher exact test. Values of P ≤ .05 were considered significant. RESULTS: 6 dogs were recruited in each group; results for 1 dog in the LaOVH group were excluded from further analysis due to free abdominal fluid detected during surgery. Median surgery time was significantly shorter and median total incision length was longer for the OS group (23 minutes; 106 mm), compared to the LaOVH group (37 minutes; 38 mm). No other results differed significantly between groups. CLINICAL RELEVANCE: Although fewer patients in the LaOVH group required rescue analgesia, this was not statistically significant. Therefore, our results could not prove previously suggested advantages of LaOVH (eg, less perioperative pain or faster recovery) in dogs with pyometra. Additionally, for the LaOVH group, the median surgical time was approximately 50% longer, an assistant was needed, and specialized equipment was required.
- 1 March 2024
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 262 (3) , 1-7
Open AccessAdvantages of laparoscopic-assisted ovariohysterectomy versus open ovariohysterectomy for dogs with pyometra not detected in randomized clinical trial
OBJECTIVE: To compare results for surgery time, perioperative pain, need for rescue analgesia, variables, serum C-reactive protein concentration, and postoperative complications for dogs with pyometra treated with laparoscopic-assisted ovariohysterectomy (LaOVH) versus open-surgery (OS) ovariohysterectomy. ANIMALS: 12 client-owned dogs with pyometra between June 1, 2016, and December 31, 2019. METHODS: Dogs enrolled in this prospective single-center randomized clinical trial had pyometra confirmed by history, physical examination, ultrasonography, and blood work and were randomly assigned to treatment group LaOVH or OS. Differences in results for variables of interest were compared between groups using the Mann-Whitney U test, except the number of dogs requiring rescue analgesia was analyzed using the Fisher exact test. Values of P ≤ .05 were considered significant. RESULTS: 6 dogs were recruited in each group; results for 1 dog in the LaOVH group were excluded from further analysis due to free abdominal fluid detected during surgery. Median surgery time was significantly shorter and median total incision length was longer for the OS group (23 minutes; 106 mm), compared to the LaOVH group (37 minutes; 38 mm). No other results differed significantly between groups. CLINICAL RELEVANCE: Although fewer patients in the LaOVH group required rescue analgesia, this was not statistically significant. Therefore, our results could not prove previously suggested advantages of LaOVH (eg, less perioperative pain or faster recovery) in dogs with pyometra. Additionally, for the LaOVH group, the median surgical time was approximately 50% longer, an assistant was needed, and specialized equipment was required.